Transgene Biotek Ltd. (BSE: 526139) is a Sangareddy, Telangana-based company in the Biological Products industry. With a market capitalisation of ₹19 Cr, it ranks #4,446 by market cap among the 6,197 Indian listed companies on FinBizNet, and #4 of 5 in Biological Products. At ₹2.64 (as of 16 Nov 2026), the share price is 33.5% below its 52-week high of ₹3.97 and 44.3% above its 52-week low of ₹1.83. The share price is down 22.1% over one year and down 11.4% over three months.
| Current Price | ₹2.64 |
|---|---|
| Market Cap | ₹19 Cr |
| BSE Code | 526139 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Biotechnology |
| Sub-Industry | Biotechnology > Biological Products |
| P/E Ratio | Not meaningful (loss) |
| Return on Equity | -17.96% |
| Return on Assets | -0.32% |
| 52-Week Range | ₹1.83 – ₹3.97 |
| 1-Year Price Change | -22.1% |
| 3-Month Price Change | -11.4% |
| Beta (1Y) | 0.77 |
| Headquarters | Sangareddy, Telangana |
| Website | www.transgenebiotek.com |
| Revenue | ₹0 Cr |
|---|---|
| Net Profit | ₹-0 Cr |
| Net Margin | -650.0% |
| EPS (Basic) | ₹0.05 |
| Basis | standalone |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Transgene Biotek Ltd. reported revenue of ₹0 Cr in Q1 FY27, up 20.0% from ₹0 Cr in Q1 FY26 and up 20.0% from ₹0 Cr in Q4 FY26. It posted a net loss of ₹0 Cr for the quarter, against a net loss of ₹0 Cr in Q1 FY26. Across the 6 quarters from Q4 FY25 to Q1 FY27, quarterly revenue ranged from ₹0 Cr (Q4 FY26) to ₹0 Cr (Q4 FY25). The company reported a net loss in 6 of these 6 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q1 FY27 | ₹0 Cr | −₹0 Cr | −650.0% |
| Q4 FY26 | ₹0 Cr | −₹0 Cr | −920.0% |
| Q3 FY26 | ₹0 Cr | −₹0 Cr | −740.0% |
| Q2 FY26 | ₹0 Cr | −₹0 Cr | −780.0% |
| Q1 FY26 | ₹0 Cr | −₹0 Cr | −860.0% |
| Q4 FY25 | ₹0 Cr | −₹1 Cr | −887.5% |
Standalone figures (₹ crore, XBRL filings).
Delivery averaged 85.0% of traded volume across 15 BSE sessions (21 Oct 2026 – 13 Nov 2026).
Transgene Biotek Limited, a biotechnology company, provides research and development services for bulk drugs in India. It offers a portfolio of oncology drugs, oral drug delivery, and biogenerics. The company provides TrabiDHA for use in health food, baby food/formula, health supplement, and chicken and animal feed markets; Tacrolimus, a drug that suppresses the immune system and is used to prevent rejection of transplanted organs; and Orlistat (tetrahydrolipstatin), a lipase inhibitor that blocks about one-third of intestinal fat absorption. The company was incorporated in 1990 and is based in Sangareddy, India.
1. Bulk Drugs-This segment engages in the research and development of hepatitis B vaccines in India. It offers oncology drugs, oral drug delivery, and biogenerics. It offers TrabiDHA for use in health foods, baby food/formulas, health supplements, and chicken and animal feed; Tacrolimus, a drug that suppresses the immune system and is used to prevent rejection of transplanted organs; and Orlistat (tetrahydrolipstatin), a lipase inhibitor that blocks about one-third of intestinal fat absorption. 2. Diagnostic Services-This segment provides diagnostic services. 3. CRO Services-This segment provides clinical research organization services. 4. Unallocated Other Income-0
1. Bulk Drugs-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Biocon Limited | ₹59,929 Cr | 131.2 | 1.15% | ₹4,389 Cr | -4.3% |
| Hester Biosciences Ltd | ₹1,985 Cr | 35.7 | 16.55% | ₹98 Cr | +46.0% |
| Zenotech Laboratories Ltd | ₹241 Cr | n/m | -1.12% | — | -22.5% |
| Transgene Biotek Ltd. | ₹19 Cr | n/m | -17.96% | ₹0 Cr | -22.1% |
| Hindustan Bio Sciences Ltd | ₹7 Cr | n/m | -9.12% | — | -0.4% |
Listed by market capitalisation. Ratios are shown for context only.
Transgene Biotek Ltd. is trading at ₹2.64, with a market capitalisation of ₹19 Cr.
Transgene Biotek Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Biotechnology space (Biotechnology > Biological Products).
Transgene Biotek Ltd. has a return on equity of -17.96%.
Transgene Biotek Ltd. is listed on the BSE under the scrip code 526139.
Transgene Biotek Ltd.'s share price is down 22.1% over one year and down 11.4% over three months. Its 52-week range is ₹1.83 to ₹3.97.
In Q1 FY27, Transgene Biotek Ltd. reported revenue of ₹0 Cr and net profit of ₹-0 Cr, with basic EPS of ₹0.05 (standalone, parsed from the company's exchange filing).
Transgene Biotek Ltd. reported revenue of ₹0 Cr in Q1 FY27, up 20.0% from ₹0 Cr in Q1 FY26 and up 20.0% from ₹0 Cr in Q4 FY26.
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.